Orient Pharma Co., Ltd. (TPEX:4166)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
26.05
-0.25 (-0.95%)
May 8, 2026, 1:30 PM CST
Market Cap5.81B -12.9%
Revenue (ttm)1.40B +14.5%
Net Income208.44M +94.1%
EPS0.90 +87.9%
Shares Out223.04M
PE Ratio28.80
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume281,530
Average Volume271,703
Open26.60
Previous Close26.30
Day's Range26.05 - 26.60
52-Week Range22.30 - 40.00
Beta0.12
RSI51.33
Earnings DateAug 13, 2026

About Orient Pharma

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan. [Read more]

Sector Healthcare
Founded 2008
Employees 173
Stock Exchange Taipei Exchange
Ticker Symbol 4166
Full Company Profile

Financial Performance

In 2025, Orient Pharma's revenue was 1.40 billion, an increase of 14.52% compared to the previous year's 1.22 billion. Earnings were 208.44 million, an increase of 94.12%.

Financial Statements